Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.

Authors

Rodolfo Sacco¹, Michela Antonucci², Irene Bargellini³, Sara Marceglia⁴, Valeria Mismas¹, Giuseppe Cabibbo⁵

Affiliations

¹ Department of Gastroenterology, Pisa University Hospital, Pisa, Italy.
² Section of Radiology - Di.Bi.Me.F., University of Palermo, Palermo, Italy.
³ Department of Radiology, Pisa University Hospital, Pisa, Italy.
⁴ Department of Engineering, University of Trieste, Trieste, Italy.
⁵ Section of Gastroenterology - Di.Bi.M.I.S., University of Palermo, Palermo, Italy.

PMID: 26270206
DOI: 10.2217/FON.15.173

No abstract available

Keywords: HCC; TACE; combination therapy; intermediate stage; sorafenib.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Hepatocellular / pathology*
Carcinoma, Hepatocellular / therapy*
Chemoembolization, Therapeutic / methods*
Combined Modality Therapy
Humans
Liver Neoplasms / pathology*
Liver Neoplasms / therapy*
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Sorafenib

Substances

Antineoplastic Agents
Phenylurea Compounds
Protein Kinase Inhibitors
Niacinamide
Sorafenib